개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 607 - 615 (9page)
이용수
초록· 키워드
오류제보하기
Purpose OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phaseI dose-escalation study of OPB-31121 was conducted to determine maximum-tolerateddose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients withadvanced solid tumors.
Materials and MethodsPatients received OPB-31121 once daily for 28 days of each cycle followed by 2 weeks rest.
A standard 3+3 design was used for dose-escalation. Safety and response were evaluatedby the National Cancer Institute–Common Terminology Criteria for Adverse Events (NCICTCAE)ver. 3.0 and Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.0, respectively.
ResultsTwenty-five patients were treated with OPB-31121 at five dose levels: 100 mg (n=4), 200mg (n=3), 400 mg (n=3), 600 mg (n=7), and 800 mg (n=8). Seven patients discontinuedtreatment during cycle 1 for various reasons other than study drug-related adverse events.
Among 18 patients who were evaluable for dose-limiting toxicity (DLT), three DLTs wereobserved: one DLT (grade 3 vomiting) at 600 mg and two DLTs (grade 3 vomiting, grade 3diarrhea) at 800 mg. The MTD was determined as 800 mg/day. Common adverse eventswere gastrointestinal adverse event including nausea (84%), vomiting (80%), and diarrhea(72%). Pharmacokinetics did not demonstrate dose-proportionality of OPB-31121. Eightpatients had stable disease and 10 patients had disease progression. Two patients (1 coloncancer, 1 rectal cancer) showed tumor shrinkage. One gastric cancer patient continuedtreatment up to cycle 13 before disease progression.
ConclusionThis study demonstrates feasibility of STAT3 inhibition in patients with advanced solid tumor.
OPB-31121, at the MTD of 800 mg/day, was safe and relatively well tolerated, and has apreliminary antitumor activity.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Alas S / 2003 / Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis / Clin
Alvarez JV / 2006 / Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epiderm
Baxter EJ / 2005 / Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders / Lancet 365 : 1054 ~ 1061
Bendell JC / 2014 / Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors / Cancer Chemother Ph
Calvisi DF / 2006 / Ubiquitous activation of Ras and Jak/Stat pathways in human HCC / Gastroenterology 130 : 1117 ~ 1128
Alvarez JV / 2006 / Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epiderm
Baxter EJ / 2005 / Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders / Lancet 365 : 1054 ~ 1061
Bendell JC / 2014 / Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors / Cancer Chemother Ph
Calvisi DF / 2006 / Ubiquitous activation of Ras and Jak/Stat pathways in human HCC / Gastroenterology 130 : 1117 ~ 1128
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Cancer Research and Treatment
2019 .01
-
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Cancer Research and Treatment
2016 .01
-
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
Cancer Research and Treatment
2015 .01
-
Potential application of Natural agents derived from traditional Chinese Medicine for cancer therapy
대한동의병리학회 학술대회논문집
2015 .10
-
Effect of STAT3 on Lysophosphatidic Acid-Induced Oral Cancer Cell Invasion
치위생과학회지
2019 .01
-
Solid Tumors in Children and Adolescents
Journal of Korean Medical Science
2018 .01
-
A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer
Journal of Gynecologic Oncology
2024 .01
-
Association Study of Single-Nucleotide Polymorphisms of STAT2/STAT3/IFN-γ Genes in Cervical Cancer in Southern Chinese Han Women
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Cytokine Signaling in Tumor Progression
Immune Network
2017 .08
-
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
Gut and Liver
2024 .01
-
T Cell-Specific Knockout of STAT3 Ameliorates Dextran Sulfate Sodium-Induced Colitis by Reducing the Inflammatory Response
Immune Network
2018 .08
-
STAT3 as a Potential Target for Tumor Suppressive Effects of 15-Deoxy-Δ12,14-prostaglandin J2 in Triple Negative Breast Cancer
대한암예방학회지
2021 .09
-
Gallic Acid I nhibits STAT3 Phosphorylation and Alleviates DDS-induced Colitis via Regulating Cytokine Production
동의생리병리학회지
2016 .10
-
Gallic Acid Inhibits STAT3 Phosphorylation and Alleviates DDS-induced Colitis via Regulating Cytokine Production
동의생리병리학회지
2016 .01
-
Immunotherapy in Pediatric Solid Tumors
Clinical Pediatric Hematology-Oncology
2020 .01
-
Phase I Clinical Trial of Intraperitoneal Paclitaxel Combined with Systemic S-1 Plus Oxaliplatin for Advanced or Recurrent Gastric Cancer with Peritoneal Metastasis: The PIPS-GC trial
대한임상종양학회 학술대회지
2021 .06
-
3,3"-Diindolylmethane Inhibits Flt3L/GM-CSF-induced-bone Marrow-derived CD103＋ Dendritic Cell Differentiation Regulating Phosphorylation of STAT3 and STAT5
Immune Network
2015 .12
-
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
Cancer Research and Treatment
2024 .07
-
A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis in mice via inhibition of hepatic stellate cell activation
한국실험동물학회 학술발표대회 논문집
2018 .01
-
Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
Intestinal research
2020 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0